EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients

Philippa von der Schulenburg, Georg M N Behrens iD, Markus Hoffmann iD, Alexandra Linke, Inga Nehlmeier, Amy Madeleine Kempf, Metodi Stankov iD, Marc Lütgehetmann, Jacqueline Jahnke-Triankowski, Marylyn M Addo iD, Lutz Fischer, Ansgar W Lohse und 3 weitere

Viruses · 2024

DOI: 10.3390/v16121942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Philippa von der Schulenburg und 14 weiteren Autor:innen. Beteiligte Einrichtung: I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany. Hauptthemen laut MEDLINE: Liver Transplantation, COVID-19, Antibodies, Viral, Immunization, Secondary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DFG, DZIFTTU, COVID-19-Research Network Lower Saxony (COFONI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The efficacy of monovalent BNT162b2 Omicron XBB.1.5 booster vaccination in liver transplant recipients (LTRs) has yet to be described, particularly regarding the immune response to emerging variants like JN.1.

Methods

This study evaluated humoral and cellular immune responses in 34 liver transplant recipients (LTRs) with varying SARS-CoV-2 immune histories before and after receiving a BNT162b2 Omicron XBB.1.5 booster vaccination. The assessment involved variant-specific serology, pseudovirus neutralization tests, and Interferon-γ release assays.

Results

Participants had a median of four prior vaccinations, with 91.2% having a history of infection. Post-vaccination, significant increases in both Wuhan anti-S and Omicron-specific IgG antibodies and improved neutralization of B.1, XBB.1.5, and JN.1 pseudovirus particles were observed. Also, T-cell responses significantly increased post-vaccination. However, 17.6% of LTRs had no neutralizing antibodies against XBB.1.5 and JN.1, while 100% of healthy controls did. Shortly after vaccination, 18% of patients developed mild COVID-19. These LTRs had particularly low immune responses at baseline.

Conclusions

The monovalent XBB.1.5 booster improved overall SARS-CoV-2-specific immunity. However, some LTRs still showed low or undetectable immune responses, indicating that ongoing monitoring and further booster doses are necessary in this high-risk group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationCOVID-19Antibodies, ViralImmunization, SecondaryAntibodies, NeutralizingSARS-CoV-2Transplant RecipientsCOVID-19 VaccinesHumansFemaleMaleMiddle AgedAdultAgedBNT162 VaccineVaccinationImmunity, HumoralImmunity, CellularImmunoglobulin G

Stichwörter der Autor:innen

COVID-19JN.1SARS-CoV-2XBB.1.5cellular immune responsehumoral immune responseimmunosuppressionliver transplantationvaccination

Substanzen

Antibodies, ViralAntibodies, NeutralizingCOVID-19 VaccinesBNT162 VaccineImmunoglobulin G

Autor:innen und Institutionen

  • I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
  • Department of Rheumatology and Immunology, Hannover Medical School, 30625 Hannover, Germany.
  • German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 38124 Braunschweig, Germany.
  • Infection Biology Unit, German Primate Centre-Leibniz Institute for Primate Research, 37077 Göttingen, Germany.
  • Faculty of Biology and Psychology, Georg-August-University Göttingen, 37073 Göttingen, Germany.
  • German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, 38124 Braunschweig, Germany.

ORCID-Profile: Georg M N Behrens, Markus Hoffmann, Metodi Stankov, Marylyn M Addo, Stefan Pöhlmann, Julian Schulze Zur Wiesch

Förderung

  • DFG
  • DZIFTTU
  • COVID-19-Research Network Lower Saxony (COFONI)
  • DAMP Stiftung
  • Deutsche Forschungsgesellschaft (DFG, German Research Foundation) CRC1328 project A12
  • CRC1648 project C4
  • DZIF
  • EU project UNDINE

Zitieren

APA

von der Schulenburg, P., Behrens, G. M. N., Hoffmann, M., Linke, A., Nehlmeier, I., Kempf, A. M., Stankov, M., Lütgehetmann, M., Jahnke-Triankowski, J., Addo, M. M., Fischer, L., Lohse, A. W., Pöhlmann, S., Schulze Zur Wiesch, J., & Sterneck, M. (2024). Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients. Viruses. https://doi.org/10.3390/v16121942

Vancouver

von der Schulenburg P, Behrens GMN, Hoffmann M, Linke A, Nehlmeier I, Kempf AM, et al. Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients. Viruses. 2024. doi:10.3390/v16121942

BibTeX
@article{vonderSchulenburg2024,
  author = {von der Schulenburg, Philippa and Behrens, Georg M N and Hoffmann, Markus and Linke, Alexandra and Nehlmeier, Inga and Kempf, Amy Madeleine and Stankov, Metodi and Lütgehetmann, Marc and Jahnke-Triankowski, Jacqueline and Addo, Marylyn M and Fischer, Lutz and Lohse, Ansgar W and Pöhlmann, Stefan and Schulze Zur Wiesch, Julian and Sterneck, Martina},
  title = {Immune Response to SARS-CoV-2 XBB.1.5 and JN.1 Variants Following XBB.1.5 Booster Vaccination in Liver Transplant Recipients},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16121942}
}
Kostenlos starten →